iifl-logo-icon 1

Parmax Pharma Ltd Share Price

47
(0.64%)
Nov 6, 2024|03:40:00 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open46.7
  • Day's High47
  • 52 Wk High54
  • Prev. Close46.7
  • Day's Low46.62
  • 52 Wk Low 24.18
  • Turnover (lac)0.61
  • P/E0
  • Face Value10
  • Book Value-1.7
  • EPS0
  • Mkt. Cap (Cr.)17.58
  • Div. Yield0
View All Historical Data
No Records Found

Parmax Pharma Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

46.7

Prev. Close

46.7

Turnover(Lac.)

0.61

Day's High

47

Day's Low

46.62

52 Week's High

54

52 Week's Low

24.18

Book Value

-1.7

Face Value

10

Mkt Cap (₹ Cr.)

17.58

P/E

0

EPS

0

Divi. Yield

0

Parmax Pharma Ltd Corporate Action

17 Sep 2024

12:00 AM

AGM

Announcement Date: 17 Sep, 2024

arrow

6 Aug 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

17 Sep 2024

12:00 AM

BookCloser

arrow

Parmax Pharma Ltd NEWS AND UPDATE

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Parmax Pharma Ltd SHAREHOLDING SNAPSHOT

06 Nov, 2024|10:52 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 30.80%

Foreign: 0.00%

Indian: 30.80%

Non-Promoter- 69.19%

Institutions: 0.00%

Non-Institutions: 69.19%

Custodian: 0.00%

Share Price

Parmax Pharma Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

4.45

4.45

4.45

4.45

Preference Capital

0

0

0

0

Reserves

-4.38

1.4

1.51

1.37

Net Worth

0.07

5.85

5.96

5.82

Minority Interest

View Balance Sheet
Y/e 31 Mar( In .Cr)Mar-2020Mar-2018Mar-2017Mar-2016

Revenue

20.91

11.9

0

0

yoy growth (%)

75.77

0

0

Raw materials

-11.26

-5.78

0

0

As % of sales

53.85

48.57

0

0

Employee costs

-2.91

-2.13

-0.01

0

View Profit & Loss
Y/e 31 Mar( In .Cr)Mar-2020Mar-2018Mar-2017Mar-2016

Profit before tax

0.73

0

0

0.01

Depreciation

-1

-1.09

0

0

Tax paid

-0.3

0

-0.01

-0.01

Working capital

-0.24

-2.57

0.01

Other operating items

View Cash Flow
Y/e 31 MarMar-2020Mar-2018Mar-2017Mar-2016

Growth matrix (%)

Revenue growth

75.77

0

0

Op profit growth

63.49

-2,069.75

12.91

EBIT growth

2,335.31

587.94

-55.19

Net profit growth

78,904.6

-106.88

108.03

View Ratios

No Record Found

Parmax Pharma Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,827.25

156.944,32,660.08863.290.755,123.6798.33

Divis Laboratories Ltd

DIVISLAB

5,939.7

92.831,54,189.464300.522,063507.93

Cipla Ltd

CIPLA

1,594.3

30.541,29,316.221,178.160.813,969.86360.74

Mankind Pharma Ltd

MANKIND

2,750.1

58.011,08,750.85634.4302,529.74240.2

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,209.5

65.921,07,835.724600.882,376222.38

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Parmax Pharma Ltd

Management

Register Office

Registrar Office

Managing Director

Umang Alkesh Gosalia

Non-Exec. & Independent Dir.

Ami R Shah

Company Sec. & Compli. Officer

Yash Vora

Independent Director

Nikhil S. Uchat

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Incorporated in Nov.94, Parmax Pharma Ltd (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara. The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmaxs pharmaceutical operations. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc. The Company then discontinued their business activities for few years due to various reasons. Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA. Antibiotic project was fully implemented from 31st May97.
Read More

Company FAQs

What is the Parmax Pharma Ltd share price today?

The Parmax Pharma Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹47 today.

What is the Market Cap of Parmax Pharma Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Parmax Pharma Ltd is ₹17.58 Cr. as of 06 Nov ‘24

What is the PE and PB ratio of Parmax Pharma Ltd?

The PE and PB ratios of Parmax Pharma Ltd is 0 and -27.35 as of 06 Nov ‘24

What is the 52 Week High and Low of Parmax Pharma Ltd?

The 52-week high/low is the highest and lowest price at which a Parmax Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Parmax Pharma Ltd is ₹24.18 and ₹54 as of 06 Nov ‘24

What is the CAGR of Parmax Pharma Ltd?

Parmax Pharma Ltd's CAGR for 5 Years at 20.81%, 3 Years at 5.30%, 1 Year at 56.71%, 6 Month at 56.34%, 3 Month at 30.70% and 1 Month at 11.91%.

What is the shareholding pattern of Parmax Pharma Ltd?

The shareholding pattern of Parmax Pharma Ltd is as follows:
Promoters - 30.80 %
Institutions - 0.00 %
Public - 69.20 %

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp